SPRY · ARS Pharmaceuticals, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 13, 2026TL;DR. New CEO outlined a pivot to targeted provider selling for neffy with a >40% 2H 2026 SG&A cut and a stated path to cash flow breakeven by end of 2027, while Q2 U.S. neffy revenue rose to $26.2 million with total market share doubling to 5% and field-targeted share at 8%; the CSU Phase 2b interim readout was pushed to Q1 2027.
- + Unique neffy prescribers more than tripled year over year to over 16,000
- + Company guides to >40% reduction in cash SG&A in 2H 2026 and a path to cash flow breakeven by end of 2027
- + Salesforce expansion completed and new CCO appointed to drive targeted provider execution
- − Cash position declined to $143.8M as cumulative losses and operating outflows continued
- − Heavy reliance on shifting prescriber habits is explicitly flagged as a slow, methodical process with no near-term spike expected
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRY
this stock
ARS Pharmaceuticals, Inc.
|
$505.19M | -59.1% | -5.5% | — | 23.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.40B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.67B | +1.2% | +20.8% | 19.6 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$57.41B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRY | -16.1% | -22.0% | -41.7% | -20.7% | -59.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -14.9% | -20.2% | -59.6% | -20.3% | -71.2% |